Prostat kanseri tanısında, serum prostatik asit fosfataz (PAP) ve prostat spesifik antijen (PSA) düzeyleri yanı sıra yeni bir parametre: siyalik asit
Başlık çevirisi mevcut değil.
- Tez No: 18209
- Danışmanlar: PROF.DR. NEVZAT BABAN
- Tez Türü: Doktora
- Konular: Onkoloji, Oncology
- Anahtar Kelimeler: Belirtilmemiş.
- Yıl: 1991
- Dil: Türkçe
- Üniversite: İstanbul Üniversitesi
- Enstitü: Sağlık Bilimleri Enstitüsü
- Ana Bilim Dalı: Belirtilmemiş.
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: 79
Özet
-66- 7, SUMMARY It is of great importance to detect the prostat hyperplasia and prostat cancer cases concerning a large portion of the society, in early stages. Today, several biochemical parameters are used to determine and to follow up the cases with hyperplasia and cancer, In this study, serum prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) levels were investigated in the control group composed of 20 healty men, ages ranging from 17 to 65; in 25 men with prostatic hyperplasia, ages ranging from 55 to 75; in 10, 9, 10 and 14 men with prostate cancer, their stages being A, B, C and D respectively, ages ranging from 55 to 75. Radio immuna assay (İÎÂ) methods were used to determine serum PAP levels and enzyme immuno assay methods were used to determine serum PSA levels. With these methods, serum PAP levels were found to be 1.39+0.66 ng/ol in the control group, 2.41±1.40 ng/ml in the hyperplasia graup and 1,39±1.07, 2.32±1.25, 9,96±8.2i, 36,S9±34.i8 ng/al in stages A, B, C and D respectively. Serum PSA levels were found to be 2.62+1.30 ng/ml in the control group, S.73±4,10 ng/ml in the hyperplasia group and 3,28±2.70, 19,33±13.29, 37.6±30,73, 186.3±83,2 ng/ml in stages A, B, C and D respectively. The difference between the serum levels of PSA In sancer stages B, C, D and the control group was ıtatîstlcally significant. On the other hand, serum PAP levels of proitate cancer cases exhibit a statistically significant difference from serum PAP levels of the control group only at stage D prostate cancer. According to these data, it is reasonable to say that P5A is a better tumor marker than-67- PAP. The difference between serum PAP and PSA levels in prostate hyperplasia cases and prostate cancer those of in stage A and B is statistically insignificant. This condition is chaotic in the detection of prostate hyperplasia and early stages of prostate cancer, The available data clearly reveal that a new parameter besides PAP and PSA is necessary to increase the efficiency in diagnosis. Serving this aim, serum sialic acid levels were investigated in the control group, prostate hyperplasia group and prostate cancer group to determine whether serum sialic acid levels are useful in diagnosis. The serum sialic acid levels determined by enzymatlc-colorimetric method were 65.75±5.59 mg/dl in the control group, 63,6±6.9 mg/dl in the hyperplasia group and 79.2819.09, 89.9B±7.D1, 92.11+12.43, 101.3+14.5 mg/dl in A, B, C and D stages respectively Df cancer group. The difference between serum sialic acid levels of the control group and the prostatic hyperplasia group was found to be statistically insignificant. However, it was demostrated that the serum sialic acid levels of cancer cases were statistically different from those of control and hyperplasia group. According to obtained data we can conclude that it is essential to determine serum sialic acid levels besides PAP and PSA in order to detect prostat cancer cases at the early stages.
Özet (Çeviri)
-66- 7, SUMMARY It is of great importance to detect the prostat hyperplasia and prostat cancer cases concerning a large portion of the society, in early stages. Today, several biochemical parameters are used to determine and to follow up the cases with hyperplasia and cancer, In this study, serum prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) levels were investigated in the control group composed of 20 healty men, ages ranging from 17 to 65; in 25 men with prostatic hyperplasia, ages ranging from 55 to 75; in 10, 9, 10 and 14 men with prostate cancer, their stages being A, B, C and D respectively, ages ranging from 55 to 75. Radio immuna assay (İÎÂ) methods were used to determine serum PAP levels and enzyme immuno assay methods were used to determine serum PSA levels. With these methods, serum PAP levels were found to be 1.39+0.66 ng/ol in the control group, 2.41±1.40 ng/ml in the hyperplasia graup and 1,39±1.07, 2.32±1.25, 9,96±8.2i, 36,S9±34.i8 ng/al in stages A, B, C and D respectively. Serum PSA levels were found to be 2.62+1.30 ng/ml in the control group, S.73±4,10 ng/ml in the hyperplasia group and 3,28±2.70, 19,33±13.29, 37.6±30,73, 186.3±83,2 ng/ml in stages A, B, C and D respectively. The difference between the serum levels of PSA In sancer stages B, C, D and the control group was ıtatîstlcally significant. On the other hand, serum PAP levels of proitate cancer cases exhibit a statistically significant difference from serum PAP levels of the control group only at stage D prostate cancer. According to these data, it is reasonable to say that P5A is a better tumor marker than-67- PAP. The difference between serum PAP and PSA levels in prostate hyperplasia cases and prostate cancer those of in stage A and B is statistically insignificant. This condition is chaotic in the detection of prostate hyperplasia and early stages of prostate cancer, The available data clearly reveal that a new parameter besides PAP and PSA is necessary to increase the efficiency in diagnosis. Serving this aim, serum sialic acid levels were investigated in the control group, prostate hyperplasia group and prostate cancer group to determine whether serum sialic acid levels are useful in diagnosis. The serum sialic acid levels determined by enzymatlc-colorimetric method were 65.75±5.59 mg/dl in the control group, 63,6±6.9 mg/dl in the hyperplasia group and 79.2819.09, 89.9B±7.D1, 92.11+12.43, 101.3+14.5 mg/dl in A, B, C and D stages respectively Df cancer group. The difference between serum sialic acid levels of the control group and the prostatic hyperplasia group was found to be statistically insignificant. However, it was demostrated that the serum sialic acid levels of cancer cases were statistically different from those of control and hyperplasia group. According to obtained data we can conclude that it is essential to determine serum sialic acid levels besides PAP and PSA in order to detect prostat cancer cases at the early stages.
Benzer Tezler
- Prostat kanserli hastalarda prostatik asit fosfataz ve prostat spesifik antijenin tanısal değeri
Başlık çevirisi yok
A. TANER SAYDERE
- Serum timidin kinaz 1 düzeyi ile prostat kanseri arasındaki ilişki
Relationship between serum level of thymidine kinase 1 with prostate cancer
FETHİ AHMET TÜREGÜN
- Prostat kanseri evrelemesinde multiparametrik prostat MR görüntülemesi ve galyum-68 PSMA pet-BT bulgularının karşılaştırılması
Comparison of multiparametric prostate MR imaging and GA-68 psma PET-CT imaging in prostate cancer staging
CAN SİCİMLİ
Tıpta Uzmanlık
Türkçe
2023
ÜrolojiSağlık Bilimleri ÜniversitesiÜroloji Ana Bilim Dalı
PROF. DR. SELAHATTİN BEDİR
- Çeşitli prostatik maniplasyonların serum serbest/ total PSA oranı üzerine etkisi
Başlık çevirisi yok
KÖKSAL ÇELİK
Tıpta Uzmanlık
Türkçe
2001
ÜrolojiSüleyman Demirel ÜniversitesiÜroloji Ana Bilim Dalı
DOÇ.DR. T. AHMET SEREL
- Prostat kanserinde inflamatuar gen varyantları ve protein seviyelerinin belirlenmesi
Determination of inflammatory gene variants and protein levels in prostate cancer
EMİNE YAĞCI
Doktora
Türkçe
2021
Tıbbi BiyolojiEskişehir Osmangazi ÜniversitesiTıbbi Biyoloji Ana Bilim Dalı
PROF. DR. HÜLYAM KURT